AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

LNSR · NASDAQ · Medical - Devices

LENSAR

Builds cataract laser systems and earns recurring revenue from procedures, leases, service, and consumables.

$8.36

After-hours close+0.09 (+1.09%)

At close$8.27(−2.25%)

Something off on this page? Send us feedback.

Profile

LENSAR, Inc.LNSRHealth Care

Sells and leases LENSAR Laser System and ALLY cataract platforms for cataract treatment and astigmatism management. Revenue is tied to installed systems, procedure licenses, patient-interface devices, leases, service, and a business base weighted toward the United States.

Designs and commercializes ophthalmic laser systems used in cataract treatment and astigmatism management. The current portfolio includes the legacy LENSAR Laser System and ALLY, a compact robotic cataract laser platform that pairs laser capability with proprietary imaging and software.

Sells and leases systems, then earns recurring revenue from procedure licenses, patient-interface devices, service, and support. Product and service revenue is weighted toward the United States, while ALLY has availability or regulatory clearance across the United States, Europe, India, Taiwan, South Korea, and other markets.

Operates as a single reportable segment and continues independently after the terminated Alcon merger. Sales and leases tend to be stronger late in the year and slower early in the year, and tariff policies affect raw-material costs for ALLY systems and patient-interface devices.

Company facts

CEONicholas T. Curtis

ListedOct 2, 2020

ExchangeNASDAQ

HeadquartersOrlando, FL

CountryUnited States

Employees150

CIK0001320350

ISINUS52634L1089

Key statistics

Market cap$101.9M

EPS (ttm)−$0.3300

P/E (ttm)−25.15

ROE10,380.3%

P/B6.85

P/S1.69

Dividend yield—

Beta0.59vs XLV 0.49

Year to date −28.8% · Average volume (30d) 156.9K

Analysts

Price target, next 12 months$11.50+38.6%Median of 3 analysts · vs the Aug 28 close

ConsensusBuy2 of 3 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $8.30

High$13.00+56.6%

Median$11.50+38.6%

Low$10.00+20.5%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Target
Aug 13, 2026	Lake Street	Reiterate		Buy	$13
Mar 18, 2026	BTIG	Upgrade	Neutral	Buy
Mar 17, 2026	BTIG	Target			$10
Mar 24, 2025	Lake Street	Downgrade	Buy	Hold

Earnings

EPS

Estimate−$0.05

ReportedDue Nov 12, 2026

Revenue

Estimate$14.3M

ReportedDue Nov 12, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 13, 2026Q2 FY26	−$0.17	$0.10	+160.6%	$14.7M	$13.7M	−6.6%	+31.48%
May 8, 2026Q1 FY26	$0.19	$1.56	+743.2%	$13.4M	$12.6M	−6.0%	+2.48%
Mar 31, 2026Q4 FY25	−$0.07	−$0.12	−80.7%	$20.3M	$12.7M	−37.6%	+0.17%
Nov 6, 2025Q3 FY25	−$0.10	−$0.31	−210.0%	$20.3M	$14.3M	−29.5%	−7.34%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$14.2M	$13.9M	$14.3M	$16.0M	$13.4M	$16.5M
Gross profit	$7.1M	$7.0M	$5.8M	$6.9M	$6.4M	$9.8M
Operating income	−$5.8M	−$6.3M	−$7.6M	−$4.9M	$2.2M	$2.1M
Net income	−$27.3M	−$1.8M	−$3.7M	−$1.5M	$36.3M	$3.5M
Diluted EPS	−$2.32	−$0.15	−$0.31	−$0.12	$0.00	$0.10
Gross margin	50.3%	50.4%	40.6%	43.3%	47.5%	59.3%
Operating margin	-40.9%	-45.1%	-52.9%	-30.7%	16.7%	12.9%

Fiscal years (4-quarter sums)FY21 $34.5M · FY22 $35.4M · FY23 $42.2M · FY24 $53.5M · FY25 $58.4M

Revenue by product · Q2 FY26

Product$13.0M · 89%

Service$1.7M · 11%

Revenue by geography · Q2 FY26

United States$10.4M · 71%

Europe$2.3M · 16%

Asia$2.0M · 13%

Other Geographical Region$62.0K · 0%

Balance sheet, Jun 30, 2026Cash & short-term investments $13.6M · Total debt $2.4M · Total assets $69.6M · Shareholders' equity $14.9M

Dividends

No dividends on record.

Ownership

Institutions 42.01%5.16M sharesInsiders 24.19%2.97M sharesOther 33.80%4.15M shares

Shares outstanding 12.28M · Float 8.71M · 70.9% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Nicholas T. Curtis · director, officer: Chief Executive Officer	1.12M	9.14%	Form 4	Jun 5, 2026
Brandes Investment Partners, LP	1.03M	8.50%	13G	May 14, 2026
BlackRock, Inc.	628.7K	5.12%	13F	May 13, 2026
William J. Phd Link · director	568.1K	4.63%	Form 4	Jun 5, 2026
Vanguard Capital Management LLC	390.1K	3.18%	13F	May 15, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.